Cell phenotype (CD23)‐dependent variation in EBV genome copy numbers within lymphoblastoid cell lines (LCL)
- 20 February 1992
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 50 (4) , 589-592
- https://doi.org/10.1002/ijc.2910500417
Abstract
Three Epstein‐Barr‐virus‐transformed lymphoblastoid cell lines (LCL) were analysed on the basis of their CD23 expression. Levels of EBV‐DNA were compared in the positive and negative subpopulations. Two lines were further analysed with regard to EBNA, cytoplasmic immunoglobulin (clg) and lytic (EA/VCA) protein expression. Both subpopulations had a similar MHC class‐11 transcription, but the CD23− subpopulation had a lower plating efficiency and a lower rate of DNA synthesis. In the B6, NAD50 and 0467.3 cell lines, CD23− cells contained 2 ± 0.2–6.4 ± 3.0 times less EBV DNA than the corresponding CD23+ population. EBNA was expressed in 81 ± 4.2%‐93 ± 3.8% of the CD23+ cells and in 0–46 ± 8.0% of the CD23− cells. No CD23+ cells in B6 or NAD50 contained any EA/VCA, while 19 ± 2.8%‐24 ± 4.2% of the CD23− cells were positive for the lytic‐cycle‐associated antigens. Of the CD23− cells, 70 ± 8.6%‐86 ± 6.0% were positive for cytoplasmic immunoglobulin compared to 14.7 ± 2.7%‐14.9 ± 1.8% in the corresponding CD23+ population. We have previously shown that only 18% of the clg‐positive cells were EBNA‐positive in the B6 line compared to 94% in the clg population. This was open to 2 alternative interpretations: loss of EBV genomes from a fraction of the cells with subsequent differentiation to secretory immunoglobulin production, or down‐regulation of EBNA expression in differentiating, EBV‐genome‐positive cells. Our present findings speak for the first alternative, indicating that a certain proportion of the cells may lose their EBV genomes in both long‐established and freshly transformed LCLs. This is accompanied by a reduced percentage of EBNA‐positive cells, the disappearance of at least one activation marker (CD23) associated with the virally induced blast transformation, and an increased synthesis of clg.Keywords
This publication has 17 references indexed in Scilit:
- CD23: a multi-functional receptor/ lymphokine?Immunology Today, 1989
- Lymphocytes activated by the epstein-barr virus to produce immunoglobulin do not express CD23 or become immortalizedInternational Journal of Cancer, 1988
- EBV-transformed lymphoblastoid cell lines down-regulate ebna in parallel with secretory differentiationInternational Journal of Cancer, 1987
- Rat c-myc oncogene is located on chromosome 7 and rearranges in immunocytomas with t(6:7) chromosomal translocationNature, 1983
- Use of Epstein-Barr virus-transformed B cell lines for the generation of immunoglobulin-producing human B cell hybridomas.The Journal of Experimental Medicine, 1982
- Alpha chain of HLA-DR transplantation antigens is a member of the same protein superfamily as the immunoglobulinsCell, 1982
- Monoclonal antibodies to epstein‐barr virus‐induced, transformation‐associated cell surface antigens: Binding patterns and effect upon virus‐specific t‐cell cytotoxicityInternational Journal of Cancer, 1982
- Purification of Mouse Immunoglobulin Heavy‐Chain Messenger RNAs from Total Myeloma Tumor RNAEuropean Journal of Biochemistry, 1980
- Cellular localization of an Epstein‐Barr virus (EBV)‐associated complement‐fixing antigen in producer and non‐producer lymphoblastoid cell linesInternational Journal of Cancer, 1973
- Relationship between the EBV-associated membrane antigen on burkitt lymphoma cells and the viral envelope, demonstrated by immunoferritin labellingInternational Journal of Cancer, 1971